Cannabix Technologies Completes Breath Collection Unit and Provides Update

CBJ Newsmakers

The Cannabix Marijuana Breathalyzer system is being developed to give law enforcement and employers a tool to enforce public safety

VANCOUVER, British Columbia, Jan. 28, 2019 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased report that it has received an initial version of its portable handheld device that will provide for easy collection of breath samples at the point of care. In collaboration with Company scientists, MistyWest Engineering of Vancouver was engaged to develop a breath collection unit (“BCU”) in late November, that would interface directly with the innovative FAIMS (field asymmetric waveform ion mobility spectrometry) based instrument for the detection of THC in human breath that Cannabix is developing. The BCU is a proprietary device that will make it easier to collect key physiologic breath sample data under different environmental conditions to determine the effects of such parameters on a ∆9-tetrahydrocannabinol (“THC”) breath sample.  BCU components were machined and assembled over the course of December and January and MistyWest has delivered an initial version of the BCU. Images of the Cannabix BCU can be seen at the Company’s website at

Cannabix will use the new BCU for the collection of multiple samples, from multiple users under a variety of conditions, in an efficient manner. The BCU is lightweight, runs on a conventional battery and includes a self-contained specialized breath sample container that integrates directly with the Company’s FAIMS detection device for analysis. The BCU has been designed to collect numerous samples required for pilot and research testing and be easy to administer by untrained personnel.

The BCU real time data display wirelessly connects to an android device for live data streaming and this data can be sent to the cloud for further analysis and storage. Currently the BCU will collect key real-time parameters of breath flow rate, total volume, relative humidity measurements, as well as carbon dioxide levels, and temperature – these measurements and others, will help Cannabix, regulators and industry scientists determine key physiologic parameters needed for standardizing a breath sample for FAIMS THC content and its decay metrics. There is currently scant information related to these critical physiologic data points available for human breath in THC smokers.

Cannabix has been building upon its promising characterization results from 2018 and with additional FAIMS cells to improve resolving power and establish repeatable results in multiple devices. Thus far testing has demonstrated the ability to isolate Δ9-tetrahydrocannabinol (“THC”) and suppress background substrates substantially. FAIMS works as an “ion blocking” technology, essentially blocking unwanted ions/analytes and allowing specified ions to pass through for detection. The characterization work has been conducted using a bench version of the FAIMS device. Cannabix scientists have been actively tuning the FAIMS device coupled to real time switchable mass spectrometry to detect key molecules and their complex pathways in the body to enable the identification of recency of use.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.  

 On behalf of the Board of Directors

“Rav Mlait”

Cannabix Technologies Inc.

For further information, contact the Company at

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities.  The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

A photo accompanying this announcement is available at